Breaking News

Cytiva Invests in Resins Manufacturing Ops in Muskegon, MI

Part of Cytiva and Pall Corp.’s $1.5 billion capacity expansion, the site will include a 168,000 sq.-ft. biomanufacturing center.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cytiva, a global life sciences leader, is investing in additional resins manufacturing operations outside of Sweden, with the acquisition of a new facility in Muskegon, MI. The new chromatography resins manufacturing site is part of Cytiva and Pall Corp.’s $1.5 billion capacity expansion investment.   Emmanuel Ligner, Danaher Group Executive and President and CEO of Cytiva, said, “This shows our leadership in action, strengthening our focus on providing customers who use our resins to manufact...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters